Ropes & Gray represented the underwriters in Biohaven Ltd.’s $287.5 million follow-on offering of 6,052,631common shares at $47.50 per share. The transaction closed on Oct. 2 and was announced in a press release.
Biohaven is a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of life-changing therapies to treat a broad range of rare and common diseases.
The deal team was led by capital markets partner Will Michener, IP transactions partner Melissa Rones and life sciences regulatory & compliance partner Kellie Combs.
Stay Up To Date with Ropes & Gray
Ropes & Gray attorneys provide timely analysis on legal developments, court decisions and changes in legislation and regulations.
Stay in the loop with all things Ropes & Gray, and find out more about our people, culture, initiatives and everything that’s happening.
We regularly notify our clients and contacts of significant legal developments, news, webinars and teleconferences that affect their industries.